. . . . . . . . . "Ofloxacin S-(-)-form"@en . . . . . . . " "@en . . . "(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid"@en . . . . . . "For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Staphylococus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Groups C/F/G), Viridans group streptococci, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens."@en . . "(S)-Ofloxacin"@en . . . . . . . . . . . . . " "@en . . . . . . . . . . . . . . . . . "approved"@en . . "Side effects include disorientation, dizziness, drowsiness, hot and cold flashes, nausea, slurring of speech, swelling and numbness in the face"@en . . "Levofloxacino"@en . . . . . . . . . . "Levofloxacin"@en . . . . . . . . . . . . . "(-)-Ofloxacin"@en . "Levofloxacin inhibits bacterial type II topoisomerases, topoisomerase IV and DNA gyrase. Levofloxacin, like other fluoroquinolones, inhibits the A subunits of DNA gyrase, two subunits encoded by the gyrA gene. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing; DNA replication and transcription is inhibited."@en . "Mainly excreted as unchanged drug in the urine. "@en . "Take without regard to meals. Take with water, drink lliberally. Taking this product with orange juice can result in reduced quinolone plasma levels. "@en . "(S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid"@en . . . . . . . . . "Enteric bacteria and other eubacteria"@en . . . . . . "Absorption of ofloxacin after single or multiple doses of 200 to 400 mg is predictable, and the amount of drug absorbed increases proportionately with the dose."@en . "L-ofloxacin"@en . . . "Levofloxacine"@en . "Levofloxacinum"@en . . . . . "100986-85-4"@en . . . . "(3S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid"@en . . . "6-8 hours"@en . . "Valerie Niddam-Hildesheim, \"Preparation of levofloxacin and forms thereof.\" U.S. Patent US20030130507, issued July 10, 2003."@en . "24-38% (to plasma proteins)"@en . "investigational"@en . "A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. [PubChem]"@en . . . . . . . . . . . . . . . . .